Alterations in gene expression profiles correlated with cisplatin cytotoxicity in the glioma U343 cell line

Genetics and Molecular Biology

Volumn 33, Issue 1, 2010, Pages 159-168

  Carminati, Patricia Oliveira ^a   Mello, Stephano Spano ^a   Fachin, Ana Lucia ^a   Junta, Cristina Moraes ^a   Sandrin Garcia, Paula ^a   Carlotti, Carlos Gilberto ^a   Donadi, Eduardo Antonio ^a   Passos, Geraldo Aleixo Silva ^a   Sakamoto Hojo, Elza Tiemi ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Apoptosis; Cisplatin; Gene expression; Glioma

Indexed keywords

CISPLATIN;

APOPTOSIS; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DNA MICROARRAY; DRUG ACTIVITY; GENE EXPRESSION; GLIOMA CELL; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

EID: 77749327445     PISSN: 14154757     EISSN: 16784685     Source Type: Journal    
DOI: 10.1590/S1415-47572010005000013     Document Type: Article

References (56)

1. Aznar S and Lacal JC (2001) Rho signals to cell growth and apoptosis. Cancer Lett 165:1-10.
2. Baker AH, Edwards DR and Murphy G (2002) Metalloproteinase inhibitors: Biological actions and therapeutic opportunities. J Cell Sci 115:3719-3727.
3. Bassi C, Mello SS, Cardoso RS, Godoy PD, Fachin AL, Junta CM, Sandrin-Garcia P, Carlotti CG, Falcão RP, Donadi EA, et al. (2008) Transcriptional changes in U343 MG-a glioblastoma cell line exposed to ionizing radiation. Hum Exp Toxicol 27:919-929.
4. Bogler O and Weller M (2002) Apoptosis in gliomas, and its role in their current and future treatment. Front Biosci 7:e339-353.
5. Boulikas T and Vougiouka M (2004) Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review). Oncol Rep 11:559-595.
6. Brabec V and Kasparkova J (2005) Modifications of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs. Drug Resist Updat 8:131-146.
7. Brown JM and Attardi LD (2005) The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 5:231-237.
8. Choi JE, Kim DS, Kim EJ, Chae MH, Cha SI, Kim CH, Jheon S, Jung TH and Park JY (2008) Aberrant methylation of ADAMTS1 in non-small cell lung cancer. Cancer Genet Cytogenet 187:80-84.
9. Cui Y, Ying Y, van Hasselt A, Ng KM, Yu J, Zhang Q, Jin J, Liu D, Rhim JS, Rha SY, et al. (2008) OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation. PLoS ONE 3:e2990.
10. Deng S, Zhou H, Xiong R, Lu Y, Yan D, Xing T, Dong L, Tang E and Yang H (2007) Over-expression of genes and proteins of ubiquitin specific peptidases (USPs) and proteasome subunits (PSs) in breast cancer tissue observed by the methods of RFDD-PCR and proteomics. Breast Cancer Res Treat 104:21-30.
11. Dennis Jr G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC and Lempicki RA (2003) DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4:P3.
12. Duale N, Lindeman B, Komada M, Olsen AK, Andreassen A, Soderlund EJ and Brunborg G (2007) Molecular portrait of cisplatin induced response in human testis cancer cell lines based on gene expression profiles. Mol Cancer 6:53.
13. Feng X, Bonni S and Riabowol K (2006) HSP70 induction by ING proteins sensitizes cells to tumor necrosis factor alpha receptor-mediated apoptosis. Mol Cell Biol 26:9244-9255.
14. Giese A, Rief MD, Loo MA and Berens ME (1994) Determinants of human astrocytoma migration. Cancer Res 54:3897-3904.
15. Golding SE, Rosenberg E, Khalil A, McEwen A, Holmes M, Neill S, Povirk LF and Valerie K (2004) Double strand break repair by homologous recombination is regulated by cell cycle-independent signaling via ATM in human glioma cells. J Biol Chem 279:15402-15410.
16. Hall PA, Jung K, Hillan KJ and Russell SE (2005) Expression profiling the human septin gene family. J Pathol 206:269-278.
17. Huang ZY, Baldwin RL, Hedrick NM and Gutmann DH (2002) Astrocyte-specific expression of CDK4 is not sufficient for tumor formation, but cooperates with p53 heterozygosity to provide a growth advantage for astrocytes in vivo. Oncogene 21:1325-1334.
18. Iwadate Y, Fujimoto S, Tagawa M, Namba H, Sueyoshi K, Hirose Mand Sakiyama S (1996) Association of p53 gene mutation with decreased chemosensitivity in human malignant gliomas. Int J Cancer 69:236-240.
19. Iwamaru A, Szymanski S, Iwado E, Aoki H, Yokoyama T, Fokt I, Hess K, Conrad C, Madden T, Sawaya R, et al. (2007) A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 26:2435-2444.
20. Jayathilaka K, Sheridan SD, Bold TD, Bochenska K, Logan HL, Weichselbaum RR, Bishop DK and Connell PP (2008) A chemical compound that stimulates the human homologous recombination protein RAD51. Proc Natl Acad Sci USA 105:15848-15853.
21. Jiang Y, Goldberg ID and Shi YE (2002) Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 21:2245-2252.
22. Kim DS, Hubbard SL, Peraud A, Salhia B, Sakai K and Rutka JT (2004) Analysis of mammalian septin expression in human malignant brain tumors. Neoplasia 6:168-178.
23. Kong L, Li Q, Wang L, Liu Z and Sun T (2007) The value and correlation between PRL-3 expression and matrix metalloproteinase activity and expression in human gliomas. Neuropathology 27:516-521.
24. Kremer BE, Adang LA and Macara IG (2007) Septins regulate actin organization and cell-cycle arrest through nuclear accumulation ofNCKmediated by SOCS7. Cell 130:837-850.
25. Kunwar S, Mohapatra G, Bollen A, Lamborn KR, Prados M and Feuerstein BG (2001) Genetic subgroups of anaplastic astrocytomas correlate with patient age and survival. Cancer Res 61:7683-7688.
26. Kuznetsov SG, Haines DC, Martin BK and Sharan SK (2009) Loss of Rad51c leads to embryonic lethality and modulation of Trp53-dependent tumorigenesis in mice. Cancer Res 69:863-872.
27. Lefranc F, Brotchi J and Kiss R (2005) Possible future issues in the treatment of glioblastomas: Special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol 23:2411-2422.
28. J, Wood 3rd WH, Becker KG, Weeraratna AT and Morin PJ (2007) Gene expression response to cisplatin treatment in drug-sensitive and drug-resistant ovarian cancer cells. Oncogene 26:2860-2872.
29. Livak KJ and Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402-408.
30. Lu Q, Longo FM, Zhou H, Massa SM and Chen YH (2009) Signaling through Rho GTPase pathway as viable drug target. Curr Med Chem 16:1355-1365.
31. Lu W, Zhou X, Hong B, Liu J and Yue Z (2004) Suppression of invasion in human U87 glioma cells by adenovirus-mediated co-transfer of TIMP-2 and PTEN gene. Cancer Lett 214:205-213.
32. Luque A, Carpizo DR and Iruela-Arispe ML (2003) ADAMTS1/METH1 inhibits endothelial cell proliferation by direct binding and sequestration of VEGF165. J Biol Chem 278:23656-23665.
33. Ma Y, Yuan RQ, Fan S, Hu C, Goldberg ID, Laterra JJ and Rosen EM (2006) Identification of genes that modulate sensitivity of U373MG glioblastoma cells to cis-platinum. Anticancer Drugs 17:733-751.
34. Ohgaki H (2005) Genetic pathways to glioblastomas. Neuropathology 25:1-7.
35. Ovaa H, Kessler BM, Rolen U, Galardy PJ, Ploegh HL and Masucci MG (2004) Activity-based ubiquitin-specific protease (USP) profiling of virus-infected and malignant human cells. Proc Natl Acad Sci USA 101:2253-2258.
36. Park CM, Park MJ, Kwak HJ, Moon SI, Yoo DH, Lee HC, Park IC, Rhee CH and Hong SI (2006) Induction of p53-mediated apoptosis and recovery of chemosensitivity through p53 transduction in human glioblastoma cells by cisplatin. Int J Oncol 28:119-125.
37. Quackenbush J (2002) Microarray data normalization and transformation. Nat Genet (Suppl) 32:496-501.
38. Reed JE, Dunn JR, du Plessis DG, Shaw EJ, Reeves P, Gee AL, Warnke PC, Sellar GC, Moss DJ and Walker C (2007) Expression of cellular adhesion molecule 'OPCML' is downregulated in gliomas and other brain tumours. Neuropathol Appl Neurobiol 33:77-85.
39. Rolen U, Kobzeva V, Gasparjan N, Ovaa H, Winberg G, Kisseljov F and Masucci MG (2006) Activity profiling of deubiquitinating enzymes in cervical carcinoma biopsies and cell lines. Mol Carcinog 45:260-269.
40. Rougemont J and Hingamp P (2003) DNA microarray data and contextual analysis of correlation graphs. BMC Bioinformatics 4:15.
41. Sellar GC, Watt KP, Rabiasz GJ, Stronach EA, Li L, Miller EP, Massie CE, Miller J, Contreras-Moreira B, Scott D, et al. (2003) OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. Nat Genet 34:337-343.
42. Shah S, Smith H, Feng X, Rancourt DE and Riabowol K (2009) ING function in apoptosis in diverse model systems. Biochem Cell Biol 87:117-125.
43. Sorenson CM, Barry MA and Eastman A (1990) Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J Natl Cancer Inst 82:749-755.
44. Suyama E, Wadhwa R, Kawasaki H, Yaguchi T, Kaul SC, Nakajima M and Taira K (2004) LIM kinase-2 targeting as a possible anti-metastasis therapy. J Gene Med 6:357-363.
45. Tallen UG, Truss M, Kunitz F, Wellmann S, Unryn B, Sinn B, Lass U, Krabbe S, Holtkamp N, Hagemeier C, et al. (2008) Down-regulation of the inhibitor of growth 1 (ING1) tumor suppressor sensitizes p53-deficient glioblastoma cells to cisplatin-induced cell death. J Neurooncol 86:23-30.
46. Torigoe T, Izumi H, Ishiguchi H, Yoshida Y, Tanabe M, Yoshida T, Igarashi T, Niina I, Wakasugi T, Imaizumi T, et al. (2005) Cisplatin resistance and transcription factors. Curr Med Chem Anticancer Agents 5:15-27.
47. Tusher VG, Tibshirani R and Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98:5116-5121.
48. Vazquez F, Hastings G, Ortega MA, Lane TF, Oikemus S, Lombardo M and Iruela-Arispe ML (1999) METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity. J Biol Chem 274:23349-23357.
49. Wong ML, KayeAHand HovensCM(2007) Targeting malignant glioma survival signalling to improve clinical outcomes. J Clin Neurosci 14:301-308.
50. Yamanaka R, Arao T, Yajima N, Tsuchiya N, Homma J, Tanaka R, Sano M, Oide A, SekijimaMand Nishio K (2006) Identification of expressed genes characterizing long-term survival in malignant glioma patients. Oncogene 25:5994-6002.
51. Yan B, Chour HH, Peh BK, Lim C and Salto-Tellez M (2006) RhoA protein expression correlates positively with degree of malignancy in astrocytomas. Neurosci Lett 407:124-126.
52. Ythier D, Larrieu D, Brambilla C, Brambilla E and Pedeux R (2008) The new tumor suppressor genes ING: Genomic structure and status in cancer. Int J Cancer 123:1483-1490.
53. Zhang P, Zhang Z, Zhou X, Qiu W, Chen F and Chen W (2006) Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line. BMC Cancer 6:224.
54. MEV software: http://tm4.org/mev.html (last date of access: November 1, 2009).
55. S.O.U.R.C.E. (Stanford Online Universal Resource for Clones and ESTs): source.stanford.edu (last date of access: October 30, 2009).
56. NCBI: http://www.ncbi.nlm.nih.gov/.